Researcher Spotlight: Samuel Yamshon, MD JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY In recent years, there has been substantial research interest in harnessing the power of the body’s own immune system to help fight lymphoma. This type…
Researcher Spotlight: Hans-Guido Wendel, MD Memorial Sloan Kettering Cancer Center Mutations in epigenetic regulators of gene expression are common in follicular lymphoma (FL), which result in altered expression of hundreds of genes. Throughcollaborative efforts with clinical and research leaders at…
Researcher Spotlight: David Scott, MBCHB, PhD BC Cancer The disease course for follicular lymphoma (FL) is highly variable, and while many patients respond to treatment, some may experience relapse or evolution of disease into a more aggressive form of lymphoma.…
Researcher Spotlight: Abner Louissaint, MD, PhD Massachussetts GEneral Hospital Follicular lymphoma (FL) is unique among lymphomas in that there are many interactions between tumor cells and the healthy immune cells in their environment. Although it’s known that this communication is…
Researcher Spotlight: Todd Fehniger, MD, PhD washington university school of medicine Natural killer (NK) cells are a type of immune cell that fight infections and cancer cells. Using advanced techniques for single-cell analysis, Dr. Fehniger’s LRF research aims to study…
Researcher Spotlight: Stephen Ansell, MD, PhD mayo clinic, rochester In addition to lymphoma B cells, a variety of other immune cells are found in the lymph nodes of patients with follicular lymphoma (FL), including diverse populations of T cells. Dr.…
Researcher Spotlight: Antonio Ferreira, PHD Brigham and Women’s Hospital The tumor microenvironment, comprised of both tumor cells and healthy cells, may play a role in growth and proliferation of malignant cells. Dr. Ferreira’s LRF research, funded under the Foundation’s larger…
Researcher Spotlight: Lorenzo Falchi, MD MEMORIAL SLOAN KETTERING CANCER CENTER For the last two decades, follicular lymphoma (FL) has been treated with traditional chemotherapy. While effective, this treatment is not considered curative and can cause a host of short- and…
Researcher Spotlight: Juan Alderuccio, MD MILLER SCHOOL OF MEDICINE OF THE UNIVERSITY OF MIAMI Relapsed or refractory follicular lymphoma (FL) is considered an incurable lymphoma malignancy, with most patients needing lifelong treatment. Loncastuximab tesirine is an antibody-drug conjugate that targets…
Researcher Spotlight: Yuxuan Liu, PhD Columbia University Medical Center Recent research has shown that genes encoding histone acetyltransferase (HAT) enzymes, EP300 and CREBBP, often become mutated in the malignant cells of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).…